國藥控股(01099.HK)“20國藥01”利率為3.27%
格隆匯7月27日丨國藥控股(01099.HK)公告,國藥控股股份有限公司(以下簡稱“發行人”或“公司”)公開發行不超過人民幣100億元(含100億元)公司債券已獲得中國證券監督管理委員會證監許可【2018】1634號文核准。國藥控股股份有限公司2020年公開發行公司債券(第一期)為本次債券的第三期發行,債券發行規模不超過27億元(含27億元)。
2020年7月24日,發行人和主承銷商在網下向合格投資者進行了簿記建檔。根據簿記建檔結果,經發行人和主承銷商充分協商和審慎判斷,最終確定期債券的票面利率為3.27%,實際發行規模為27億元。
債券票面利率在存續期內前2年固定不變,在期債券存續期內第2年末,如發行人行使調整票面利率選擇權,未被回售部分債券在債券存續期後1年的票面利率為債券存續期前2年票面年利率加上或減去調整基點,在債券存續期後1年固定不變;若發行人未行使調整票面利率選擇權,未被回售部分債券在債券存續期後1年票面利率仍維持原有票面利率不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.